Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ldn Pharma Limited manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 5 pending office actions. This volume indicates a significant amount of active prosecution and a broad engagement with the patent office across multiple pharmaceutical applications.
The portfolio is highly distributed, involving 5 distinct examiners and 5 distinct art units. This one-to-one ratio of 5 pending office actions to 5 distinct examiners suggests that the company's filings cover a wide range of technical topics. Each application is being reviewed in a different administrative environment, requiring a versatile legal strategy to address the specific requirements of each of the 5 distinct art units.
MCMILLIAN, KARA RENITA is identified as the busiest examiner for Ldn Pharma Limited. This examiner is currently handling 1 pending office action. Although designated as the busiest, this examiner only manages 1 of the 5 total pending actions, reflecting the highly decentralized nature of the company's current prosecution efforts across multiple examiners.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| MOSS, NATALIE M | 1 | 30.8% | +17.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 8d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 49d overdue |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 8d overdue |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | VALENROD, YEVGENY | 83d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1628 | 1 |
| 1613 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | SAMSELL, RILLA MARIE | 1624 | DP | Final Rejection | 20d | Pending | Dec 21, 2023 |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | VALENROD, YEVGENY | 1628 | §112 | Non-Final OA | 83d | Pending | Dec 20, 2023 |
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | 49d overdue | Pending | Jul 21, 2023 |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 1653 | §103§112 | Non-Final OA | 8d overdue | Pending | Sep 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial